{"id":"W2767506942","doi":"10.1093/neuonc/nox168.022","title":"ACTR-27. COMPLIANCE AND TREATMENT DURATION PREDICT SURVIVAL IN A PHASE 3 EF-14 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Temozolomide; Medicine; Glioblastoma; Internal medicine; Oncology; Progression-free survival; Adjuvant; Clinical trial; Overall survival; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001170893,0.0002438359,0.0007706214,0.0001632011,0.00008816232,0.00002309052,0.00008197883,0.0001065722,0.00001229159],"category_scores_gemma":[0.0002840945,0.0001656411,0.00004427235,0.0001069599,0.0001462474,0.000126193,0.00003333843,0.0001483248,0.000001590917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002438605,"about_ca_system_score_gemma":0.0001853151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005229302,"about_ca_topic_score_gemma":0.006006193,"domain_scores_codex":[0.9985049,0.0001458867,0.0004494421,0.0004087063,0.0002110174,0.0002800091],"domain_scores_gemma":[0.9984398,0.0005186769,0.0004543942,0.0003917691,0.00007498652,0.0001203454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08793387,0.007094795,0.875176,0.00003066481,0.00007818757,0.00131999,0.0004371318,0.00002559922,0.001905433,0.000009676591,0.00003247695,0.02595621],"study_design_scores_gemma":[0.3611102,0.06756461,0.5641912,0.0002000067,0.0001512362,0.0000275466,0.00008319212,0.0003365626,0.005993003,0.000004694792,0.0002117856,0.0001259471],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965026,0.00001876462,0.000005329922,0.0008469904,0.000167358,0.001967721,0.00002660646,0.00001724824,0.0004473863],"genre_scores_gemma":[0.9992665,0.00003800592,0.0002114944,0.00008514641,0.00006949547,0.0002758616,0.00002539603,0.000022088,0.000005988049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3109848,"threshold_uncertainty_score":0.675465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0269714515350125,"score_gpt":0.3109597972464867,"score_spread":0.2839883457114742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}